Author(s): RA Ducas, MD Seftel, J Ducas, C Seifer Format Abstract Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy. Keywords Arrhythmia, arsenic trioxide, promyelocytic leukaemia Declaration of Interests No conflict of interests declared. PDF https://www.rcpe.ac.uk/sites/default/files/seifer.pdf Journal Keywords: Arrhythmiaarsenic trioxidepromyelocytic leukaemia
